Clinical trials: Injury of Liver
Ischemia Reperfusion Injury
YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation
The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of ischemia reperfusion injury following liver transplantation by administering YSPSL into the liver graft directly ex vivo via the portal…
- Trial name
- YSPSL (NCT00876902)
- Testing
- recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Y's Therapeutics, Inc.
Lennox Gastaut Syndrome, Dravet Syndrome
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
- Conditions
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
- Trial name
- NCT05044819
- Testing
- Cannabidiol
- Where
- 26 sites in United States
- Volunteers
- 154 people
- Sponsor
- Jazz Pharmaceuticals
Cirrhosis, Ascites
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites.
- Conditions
- Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury
- Trial name
- NCT05309200
- Testing
- OCE-205
- Where
- 23 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Ocelot Bio, Inc
Drug-induced Liver Injury
Rechallenge, Potential Drug Induced Liver Injury (Kaiser)
Drug re-administration or rechallenge should be avoided after drug-induced liver injury (DILI) to avoid recurrent and fatal injury. Rechallenge outcomes vary considerably by drug and patient subjects.
- Trial name
- NCT01584765
- Testing
- Prescription drugs with known hepatotoxicity
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Drug-Induced Liver Injury
Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury
The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.
- Trial name
- NCT02734966
- Testing
- Magnesium Isoglycyrrhizinate Injection 100mg OD, Magnesium Isoglycyrrhizinate Injection 200mg OD, Tiopronin Injection
- Where
- 8 sites in China
- Volunteers
- 174 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Alcoholic Hepatitis
A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe…
- Trial name
- AH (NCT03432260)
- Testing
- DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Durect
Multiple Sclerosis, Relapsing-Remitting
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate…
- Trial name
- ORION (NCT05605782)
- Where
- United States
- Volunteers
- 9,000 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Drug Induced Liver Injury
Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
Cancer has moved from the tenth place to the second one over the last 100 years, being inferior to only cardiovascular diseases in morbidity and mortality.
- Trial name
- NCT05789797
- Testing
- Remaxol
- Where
- 5 sites in Russia
- Volunteers
- 368 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Hepatorenal Syndrome, Liver Cirrhosis
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Patients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death.
- Conditions
- Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury, Ascites Hepatic
- Trial name
- NCT06256432
- Testing
- Ambrisentan, Terlipressin
- Where
- 6 sites in India
- Volunteers
- 54 people
- Sponsor
- Noorik Biopharmaceuticals AG
Hemorrhage, Trauma
Quantra QStat in Trauma and Liver Transplant
This is a multi-center prospective, observational study of the Quantra System with the QStat Cartridge in trauma patients and patients undergoing liver transplant.
- Conditions
- Hemorrhage, Trauma, Liver Transplant
- Trial name
- NCT04312958
- Testing
- Quantra System
- Where
- 10 sites in United States
- Volunteers
- 397 people
- Sponsor
- HemoSonics LLC
Drug-Induced Liver Injury, Cholestatic Liver Injury
A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects
The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI)…
- Conditions
- Drug-Induced Liver Injury, Cholestatic Liver Injury, Mixed Liver Injury
- Trial name
- NCT06019936
- Testing
- MT2004 Capsule
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xi'An Aolitai Pharmaceutical Technology Co Ltd
Invasive Candidiasis, Candidemia
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin…
- Trial name
- NCT01213823
- Testing
- Does not apply
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- Pfizer
Metastatic Solid Tumors, Stage 4 Cancer
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System.
- Trial name
- NCT07224464
- Testing
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New Phase Ltd.
SARS-CoV-2
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
- Trial name
- NCT04447404
- Testing
- DUR-928
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Durect
Acute Liver Failure, Acute-On-Chronic Liver Failure
F573 for Injection for the Treatment of Liver Injury/Failure
This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial . The primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury…
- Trial name
- NCT05689645
- Testing
- F573 for injection, Sterilizing water for injection
- Where
- 10 sites in China
- Volunteers
- 97 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Acute Drug Induced Liver Injury
Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury
The purpose of this study is to explore the efficacy and the safety of polyene phosphatidylcholine Injection in patients with acute drug-induced liver injury after 2-4 weeks of treatment.
- Trial name
- NCT04595916
- Testing
- Polyene phosphatidylcholine injection 930 mg QD, Magnesium Isoglycyrrhizinate injection 200 mg QD
- Where
- 9 sites in China
- Volunteers
- 73 people
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for…
- Trial name
- NCT01276275
- Testing
- Risk of selected safety events
- Where
- Sweden
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Pulmonary Tuberculosis
Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Hepatic Injury ( ATDH ) in Subjects with Pulmonary Tuberculosis
- Trial name
- NCT02467608
- Testing
- Isoniazid with HUEXC030 and RZE, HRZE
- Where
- 18 sites in Taiwan
- Volunteers
- 557 people
- Sponsor
- Orient Pharma Co., Ltd.
Neoplasms, Liver Injury
Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury
This purpose of this study is to evaluate the evaluate the efficacy of Magnesium Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute liver injury.
- Trial name
- MAGIC (NCT01802996)
- Testing
- Magnesium Isoglycyrrhizinate Injection
- Where
- 27 sites in China
- Volunteers
- 2,040 people
- Sponsor
- Cttq